Bilirubin, indirect

Elevated indirect bilirubin indicates either excessive red blood cell destruction (hemolysis), impaired liver uptake (hepatitis, cirrhosis), or genetic conditions affecting conjugation (Gilbert's syndrome, Crigler-Najjar syndrome). High levels can cause jaundice but, unlike direct bilirubin, cannot be excreted in urine. Monitoring helps distinguish between blood disorders and liver problems, guiding appropriate treatment strategies.

Most adults benefit from yearly indirect bilirubin testing alongside total and direct bilirubin, as part of a comprehensive liver panel.

At baseline / for screening: Once every 12 months from age 30 as part of a comprehensive panel. More frequently, every 3 to 6 months, if you have known liver disease, regular alcohol intake, fatty liver (MASLD), or take hepatotoxic medication.

When monitoring an intervention or change: Mild isolated elevations, particularly indirect bilirubin in Gilbert's syndrome, don't need a specific retest cadence. When bilirubin is elevated alongside abnormal liver enzymes or other symptoms, your clinician guides the workup rather than a fixed bilirubin retest interval.

Note: Indirect bilirubin rises with hemolysis (where reticulocyte count and haptoglobin matter for follow-up). In Gilbert's syndrome, mild elevations are lifelong and don't need closer monitoring; in suspected hemolysis, retest at 2 to 4 weeks alongside hemoglobin and LDH.